Allergan Loses 'Meritless' Bid To Gut Restasis Antitrust MDL
A New York federal judge has shot down Allergan Inc.'s "meritless" effort to eviscerate multidistrict litigation that alleges antitrust violations aimed at protecting dry-eye drug Restasis, saying it's plausible that the...To view the full article, register now.
Already a subscriber? Click here to view full article